Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02679950 · ClinicalTrials.gov registry record
Understanding the Molecular and Genetic Differences Between Germ Cell Tumor at the Time of the Initial Diagnosis and at Late Relapse
A clinical trial of Neoplasms, Germ Cell and Embryonal, sponsored by Nasser Hanna.
- Completed
- Registry status
- 6
- Enrollment target
- 2
- Study locations
NCT02679950 is a study of Neoplasms, Germ Cell and Embryonal that has completed, run by Nasser Hanna. The registered enrollment target is 6 participants. The trial reports 2 study locations across 1 state.
The verdict
NCT02679950, a study of Neoplasms, Germ Cell and Embryonal, has completed, sponsored by Nasser Hanna.
- COMPLETED
- Registry status
- 6 participants
- Enrollment target
- 2
- Study locations
Study Summary
The current proposal is a pilot study. The Investigators plan to use next generation genome sequencing (NGGS) to define the molecular and genetic profiles of 3 cases of germ cell tumor (GCT) (with a component of yolk sac tumor) at the time of the initial diagnosis and 3 cases of late relapse GCT's, which are characterized by yolk sac tumor (and AFP secreting) predominant disease. Investigators seek to demonstrate the feasibility of obtaining tissue biopsies (either archived or new biopsy) and utilization of NGGS in studying the molecular and genetic relationships between GCT's (with a component of yolk sac tumor) at the time of diagnosis and GCT's at the time of late relapse. This study will also provide preliminary information on genetic alterations, which may be a hypothesis for generating another study.
Conditions Studied
Interventions
- GENETIC Next generation genome sequencing
Study Locations (2)
Indiana
- Indiana University Health Hospital - Indianapolis
- Indiana University Health Melvin and Bren Simon Cancer Center - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2015-11-20 |
| Est. Completion | 2017-04-25 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02679950
The ClinicalTrials.gov registry entry for NCT02679950 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nasser Hanna, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neoplasms, Germ Cell and Embryonal appearing as the primary indexed condition, and to 1 intervention - of which Next generation genome sequencing is the first listed.
NCT02679950 reports 2 study locations spanning 1 distinct geographic area - top geographies include Indiana.
Frequently Asked Questions
What is clinical trial NCT02679950 about?
NCT02679950 is a clinical study titled "Understanding the Molecular and Genetic Differences Between Germ Cell Tumor at the Time of the Initial Diagnosis and at Late Relapse". The current proposal is a pilot study. The Investigators plan to use next generation genome sequencing (NGGS) to define the molecular and genetic profiles of 3 cases of germ cell tumor (GCT) (with a component of yolk sac tumor) at the time of the initial diagnosis and 3 cases of late relapse GCT's, ...
What is the current status of trial NCT02679950?
This trial is currently completed. The enrollment target is 6 participants. The study started on 2015-11-20. Estimated completion is 2017-04-25.
What conditions does trial NCT02679950 study?
This clinical trial studies the following conditions: Neoplasms, Germ Cell and Embryonal.
What interventions are being tested in trial NCT02679950?
The interventions under investigation include: Next generation genome sequencing (GENETIC).
Who is sponsoring clinical trial NCT02679950?
This trial is sponsored by Nasser Hanna, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02679950 being conducted?
This trial has 2 study locations across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.